Full Press Release Details
Mar. 19, 2024
News -
Broadcasts
NRx News
One America News interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing how Ketamine can reduce Suicidal Ideation.
Share
NRXP Positive Sentiment
One America News interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals
Key Takeaway: In a recent interview with One America News, Dr. Jonathan C. Javitt, the Chief Scientist and Founder of NRx Pharmaceuticals, discussed the potential of Ketamine in reducing suicidal ideation. The conversation emphasized the importance of exploring new treatment options for mental health issues. Dr. Javitt's insights provide valuable perspectives on this critical topic.
Price reaction · baseline $4.898 (2024-03-19T18:55:00.000Z) · hit during market hours · 2 other NRXP headline(s) in the window, move may be shared
day 0 close · peak
-1.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Interview highlights innovative use of Ketamine.
- Focus on reducing suicidal ideation is crucial.
- Expert insights from Dr. Javitt enhance credibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression
Frequently Asked Questions
What did Dr. Javitt discuss in the interview?
Dr. Javitt discussed how Ketamine can help reduce suicidal ideation.
Who is Jonathan C. Javitt?
Jonathan C. Javitt is the Chief Scientist and Founder of NRx Pharmaceuticals.
What is the significance of Ketamine in mental health?
Ketamine is being explored as a potential treatment for reducing suicidal thoughts.